CYLD expression in dendritic cells involved in the immunoregulation of pulmonary adenocarcinoma via NF-κB pathway

References

• Khosravi N, Caetano MS, Cumpian AM, et al. IL22 promotes kras-mutant lung cancer by induction of a protumor immune response and protection of stemness properties. Cancer Immunol Res. 2018;6(7):788–797.
   PubMed Web of Science ®Google Scholar
• Reppert S, Boross I, Koslowski M, et al. A role for T-bet-mediated tumour immune surveillance in anti-IL-17A treatment of lung cancer. Nat Commun. 2011;2(1):600.
   PubMedGoogle Scholar
• Caronni N, Simoncello F, Stafetta F, et al. Downregulation of membrane trafficking proteins and lactate conditioning determine loss of dendritic cell function in Lung Cancer. Cancer Res. 2018;78(7):1685–1699.
   PubMed Web of Science ®Google Scholar
• Li R, Fang F, Jiang M, et al. STAT3 and NF-kappaB are simultaneously suppressed in dendritic cells in Lung Cancer. Sci Rep. 2017;7(1):45395.
   PubMedGoogle Scholar
• Lee JM, Lee M-H, Garon E, et al. Phase I trial of intratumoral injection of ccl21 gene-modified dendritic cells in Lung Cancer elicits tumor-specific immune responses and CD8(+) T-cell infiltration. Clin Cancer Res. 2017;23(16):4556–4568.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Hu X, Hu Y, et al. Anti-CD40-induced inflammatory E-cadherin + dendritic cells enhance T cell responses and antitumour immunity in murine Lewis lung carcinoma. J Exp Clin Cancer Res. 2015;34:11.
   PubMed Web of Science ®Google Scholar
• Wang Y, Huang H, Yao S, et al. A lipid-soluble extract of Pinellia pedatisecta Schott enhances antitumor T cell responses by restoring tumor-associated dendritic cell activation and maturation. J Ethnopharmacol. 2019;241:111980.
   PubMed Web of Science ®Google Scholar
• Lee C, Jose L, Shim K, et al. Influenza mimetic protein-polymer nanoparticles as antigen delivery vehicles to dendritic cells for cancer immunotherapy. Nanoscale. 2019;11(29):13878–13884.
   PubMed Web of Science ®Google Scholar
• Zhang J, Chen Y, Chen K, et al. IL-33 drives the antitumour effects of dendritic cells via upregulating CYLD expression in pulmonary adenocarcinoma. Artif Cells Nanomed Biotechnol. 2019;47(1):1335–1341.
   PubMed Web of Science ®Google Scholar
• Alameda JP, et al. CYLD regulates keratinocyte differentiation and skin cancer progression in humans. Cell Death Dis. 2011;2:e208.
   PubMed Web of Science ®Google Scholar
• Yang Y, Ran J, Sun L, et al. CYLD regulates noscapine activity in acute lymphoblastic leukemia via a microtubule-dependent mechanism. Theranostics. 2015;5(7):656–666.
   PubMed Web of Science ®Google Scholar
• Liu P, Xu B, Shen W, et al. Dysregulation of TNFalpha-induced necroptotic signaling in chronic lymphocytic leukemia: suppression of CYLD gene by LEF1. Leukemia. 2012;26(6):1293–1300.
   PubMed Web of Science ®Google Scholar
• Hellerbrand C, Bumes E, Bataille F, et al. Reduced expression of CYLD in human colon and hepatocellular carcinomas. Carcinogenesis. 2007;28(1):21–27.
   PubMed Web of Science ®Google Scholar
• Pannem RR, Dorn C, Ahlqvist K, et al. CYLD controls c-MYC expression through the JNK-dependent signaling pathway in hepatocellular carcinoma. Carcinogenesis. 2014;35(2):461–468.
   PubMed Web of Science ®Google Scholar
• Lim JH, Stirling B, Derry J, et al. Tumor suppressor CYLD regulates acute lung injury in lethal Streptococcus pneumoniae infections. Immunity. 2007;27(2):349–360.
   PubMed Web of Science ®Google Scholar
• Zhang LM, Zhou JJ, Luo CL. CYLD suppression enhances the pro-inflammatory effects and hyperproliferation of rheumatoid arthritis fibroblast-like synoviocytes by enhancing NF-kappaB activation. Arthritis Res Ther. 2018;20(1):219.
   Google Scholar
• Tang Y, Reissig S, Glasmacher E, et al. Alternative splice forms of CYLD mediate ubiquitination of SMAD7 to prevent TGFB signaling and promote colitis. Gastroenterology. 2019;156(3):692–707.
   PubMed Web of Science ®Google Scholar
• Wex K, Schmid U, Just S, et al. Receptor-interacting protein kinase-2 inhibition by CYLD impairs antibacterial immune responses in macrophages. Front Immunol. 2016;6:650.
   PubMed Web of Science ®Google Scholar
• Legarda D, Justus SJ, Ang RL, et al. CYLD proteolysis protects macrophages from TNF-mediated auto-necroptosis induced by lps and licensed by type I IFN. Cell Rep. 2016;15(11):2449–2461.
   PubMed Web of Science ®Google Scholar
• Srokowski CC, Masri J, Hövelmeyer N, et al. Naturally occurring short splice variant of CYLD positively regulates dendritic cell function. Blood. 2009;113(23):5891–5895.
   PubMed Web of Science ®Google Scholar
• Jang JS, Lee JH, Jung NC, et al. Rsad2 is necessary for mouse dendritic cell maturation via the IRF7-mediated signaling pathway. Cell Death Dis. 2018;9(8):823.
   PubMedGoogle Scholar
• Sun SC. CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes. Cell Death Differ. 2010;17(1):25–34.
   PubMed Web of Science ®Google Scholar
• Hahn M, Bürckert J-P, Luttenberger CA, et al. Aberrant splicing of the tumor suppressor CYLD promotes the development of chronic lymphocytic leukemia via sustained NF-kappaB signaling. Leukemia. 2018;32(1):72–82.
   PubMed Web of Science ®Google Scholar
• Gurusamy D, Clever D, Eil R, et al. Novel “elements” of immune suppression within the tumor microenvironment. Cancer Immunol Res . 2017;5(6):426–433.
   PubMed Web of Science ®Google Scholar
• Varn FS, Tafe LJ, Amos CI, et al. Computational immune profiling in lung adenocarcinoma reveals reproducible prognostic associations with implications for immunotherapy. Oncoimmunology. 2018;7(6):e1431084.
   PubMed Web of Science ®Google Scholar
• Dong Z-Y, Zhang C, Li Y-F, et al. Genetic and immune profiles of solid predominant lung adenocarcinoma reveal potential immunotherapeutic strategies. J Thoracic Oncol. 2018;13(1):85–96.
   PubMed Web of Science ®Google Scholar
• Wojas-Krawczyk K, Krawczyk P, Buczkowski J, et al. Immunotherapy of lung adenocarcinoma patient with Peptide-pulsed dendritic cells: a case report. Arch Immunol Ther Exp. 2012;60(1):69–77.
   PubMed Web of Science ®Google Scholar
• Zhang J, Ou J, Wan X. LRRC62 attenuates Toll-like receptor signaling by deubiquitinating TAK1 via CYLD. Exp Cell Res. 2019;383(1):111497.
   PubMed Web of Science ®Google Scholar
• Zhang L, Wei N, Cui Y, et al. The deubiquitinase CYLD is a specific checkpoint of the STING antiviral signaling pathway. PLoS Pathog. 2018;14(11):e1007435.
   PubMed Web of Science ®Google Scholar
• Massoumi R, Chmielarska K, Hennecke K, et al. Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. Cell. 2006;125(4):665–677.
   PubMed Web of Science ®Google Scholar
• Li Y, Huang W, Xu Y, et al. CYLD deubiquitinase negatively regulates high glucose-induced NF-kappaB inflammatory signaling in mesangial cells. BioMed Res Int. 2017;2017:1.
   Web of Science ®Google Scholar
• Jiang J, Luo Y, Qin W, et al. Electroacupuncture suppresses the NF-kappaB signaling pathway by upregulating cylindromatosis to alleviate inflammatory injury in Cerebral Ischemia/Reperfusion Rats. Front Mol Neurosci. 2017;10:363.
   PubMed Web of Science ®Google Scholar
• Reissig S, Hövelmeyer N, Weigmann B, et al. The tumor suppressor CYLD controls the function of murine regulatory T cells. J Immunol. 2012;189(10):4770–4776.
   PubMed Web of Science ®Google Scholar